TABLE 1

European Respiratory Society (ERS)/American Thoracic Society (ATS) Severe Asthma Task Force questions

1Should a monoclonal anti-IL-5 antibody be used in adults and children# with severe asthma?
2Should a measurement of a specific biomarker be used to guide initiation of treatment with a monoclonal anti-IL-5 or IL-5Rα antibody in adults and children with severe asthma? (Chosen biomarkers being FENO, peripheral or sputum eosinophils and serum periostin)
3Should a measurement of a specific biomarker be used, in addition to total IgE level, to guide initiation of treatment with a monoclonal anti-IgE antibody in adults and children with severe asthma? (Chosen biomarkers being FENO, peripheral or sputum eosinophils and serum periostin)
4Should a long-acting inhaled muscarinic antagonist be used in adults and children with severe asthma?
5Should a macrolide (i.e. azithromycin, clarithromycin) be used in adults and children with severe asthma?
6Should a monoclonal anti-IL-4Rα be used in adults and children with severe asthma?

IL: interleukin; R: receptor; FENO: exhaled nitric oxide fraction. #: for the purposes of this guideline, age >5 years.